New Cervical Cancer Screening Guidelines: ACS & HRSA Updates (2026)

Cervical cancer screening recommendations have been updated at the close of 2025 and into early 2026, with both the American Cancer Society (ACS) and the Health Resources and Services Administration (HRSA) endorsing the inclusion of self-collected HPV tests as an acceptable screening method. These updates aim to broaden access to potentially life-saving screenings, particularly for individuals who face barriers to traditional methods. The changes reflect a growing body of evidence supporting the accuracy and feasibility of self-sampling for human papillomavirus (HPV), the virus responsible for nearly all cervical cancers.

The Shift Towards Primary HPV Testing

Both the ACS and HRSA now prioritize primary HPV testing for individuals aged 30-65 at average risk. This means the initial screening test focuses directly on detecting the presence of high-risk HPV types, which are known to cause approximately 70% of cervical cancers. HPV is a very common virus spread through intimate contact, and while most infections clear on their own, persistent infections with high-risk types can lead to cellular changes that may eventually develop into cancer. If primary HPV testing isn’t available, both organizations recommend “co-testing,” which combines an HPV test with a Pap test (also known as cytology). A Pap test examines cells from the cervix for abnormalities. If neither of these options are available, a Pap test alone can be used.

Expanding Access with Self-Collection

Traditionally, HPV and Pap tests required a healthcare provider to collect samples during a pelvic exam. This presented challenges for some individuals, including those with limited access to healthcare, those who experience anxiety or discomfort with pelvic exams, or those living in rural areas with fewer healthcare facilities. Recognizing these barriers, both the ACS and HRSA now acknowledge self-collected HPV tests as a valid alternative. The ACS prefers provider-collected samples but explicitly states self-collection is acceptable when access is limited. HRSA also supports screening with self-collection.

This shift opens the door for screening to occur in a wider range of settings, potentially including primary care physician offices, urgent care clinics, mobile health units, and even pharmacies. Individuals may also have the option to collect their own samples at home, further increasing convenience and accessibility. The American Cancer Society provides detailed information on the self-collection process, addressing common questions and concerns.

Navigating Differences in Screening Frequency

While the ACS and HRSA largely agree on the core principles of cervical cancer screening, there are some differences in recommended screening intervals. For individuals who undergo HPV primary testing or co-testing with provider-collected samples and receive normal results, both organizations recommend repeat screening in five years. However, the ACS specifies that those who self-collect their HPV samples and have normal results should be screened again in three years. This distinction is not included in the HRSA guidelines. If only a Pap test is performed, and results are normal, screening should occur every three years, regardless of collection method.

When Can Screening Be Stopped?

Both organizations agree that screening can generally be discontinued at age 65 if previous test results have been consistently normal. The ACS provides more specific criteria, recommending that individuals have had a decade of normal results – either negative HPV tests at ages 60 and 65, or three consecutive negative Pap tests, with the most recent at age 65. HRSA’s guidelines are less specific regarding past results, simply recommending cessation of screening at age 65.

Age of Screening Initiation: A Point of Divergence

One notable difference lies in the recommended age to begin screening. The ACS suggests starting at age 25, citing the rarity of cervical cancer in younger individuals. HRSA, however, recommends Pap tests every three years between ages 21 and 29, transitioning to HPV primary testing or co-testing at age 30.

What This Means for Patients and Providers

For most patients, the specific screening test offered will likely depend on what their healthcare provider offers. Given the preference for HPV primary testing by both organizations, it’s anticipated that more providers will adopt this method in the coming years. The HRSA guidelines also carry significant weight with insurance companies, with most private insurers required to cover recommended testing options and follow-up care without copays starting in 2027.

The availability of self-collected HPV tests is expected to significantly expand access to screening, particularly for those who may be hesitant to undergo a traditional pelvic exam or who lack convenient access to gynecological care. This could lead to earlier detection of precancerous changes and ultimately reduce the incidence of cervical cancer.

Understanding HPV and Cervical Cancer Risk

It’s critical to remember that HPV infection is extremely common, with most sexually active individuals contracting the virus at some point in their lives. However, only persistent infections with high-risk HPV types pose a significant risk of developing cervical cancer. Regular screening is crucial for identifying these persistent infections and allowing for timely intervention, such as treatment of precancerous cells.

The Evolving Landscape of Cervical Cancer Prevention

The updated guidelines represent a significant step forward in cervical cancer prevention, reflecting advancements in our understanding of HPV and the development of more effective screening methods. The ongoing evaluation of these guidelines and the continued development of latest technologies will undoubtedly shape the future of cervical cancer screening. Anyone with questions or concerns about cervical cancer screening should consult with a healthcare provider to determine the best course of action for their individual needs.